March 1973

Chemotherapy of Lymphoma With Mechlorethamine and Vinblastine

Author Affiliations

Duarte, Calif; San Francisco; Los Angeles; Seattle

From the Western Cooperative Cancer Chemotherapy Group, City of Hope National Medical Center, Duarte, Calif (Dr. Solomon); University of Southern California School of Medicine, Los Angeles (Drs. Bateman, Lukes, and Weiner); University of Washington Medical School and Kings County Central Blood Bank, Seattle (Dr. Donohue); and University of California at San Francisco Medical Center (Edwin M. Jacobs, MD).

Arch Intern Med. 1973;131(3):407-417. doi:10.1001/archinte.1973.00320090097011

To determine the relative efficacy of mechlorethamine hydrochloride and vinblastine sulfate, 172 patients with Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma were randomly assigned to receive one or the other of these agents. If treatment with the first compound failed, each patient was to be treated with the second. No significant differences were found between the therapeutic results obtained with these two drugs in any of these illnesses. The Rye classification for Hodgkin's disease was not found to be of prognostic value for response to these agents. The patients with nodular, poorly differentiated lymphocytic lymphoma according to the Gall-Rappaport classification for non-Hodgkin's lymphoma, responded significantly better to mechlorethamine than to vinblastine, and their response rate with the alkylating agent was significantly higher than that of the other persons with non-Hodgkin's lymphoma.